Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company's novel DNA intercalator, AS1413 (amonafide L-malate), for the treatment of secondary acute myeloid leukaemia (secondary AML)...